Microbix Attending & Presenting at IPVS 2026Accesswire · 5 days ago
MBX Biosciences to Participate in Upcoming November Investor ConferencesGlobeNewsWire · Oct 13, 2026
MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?Defense World · Sep 30, 2026
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DEDefense World · Sep 25, 2026
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)Seeking Alpha · Sep 23, 2026
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.63 | -$0.78 | Miss |
| May 7, 2026 | -$0.62 | -$0.51 | Beat |
| Mar 12, 2026 | -$0.64 | -$0.49 | Beat |
| Nov 6, 2025 | -$0.73 | -$0.63 | Beat |
| Aug 7, 2025 | -$0.77 | -$0.58 | Beat |
| May 12, 2025 | -$0.81 | -$0.71 | Beat |